-
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group ESMO Open (IF 7.3) Pub Date : 2024-03-18 L. Weiss, L.E. Fischer, V. Heinemann, F. Gieseler, T. Hoehler, J. Mayerle, D. Quietzsch, A. Reinacher-Schick, M. Schenk, G. Seipelt, J.T. Siveke, M. Stahl, U. Kaiser, D.T. Waldschmidt, K. Dorman, D. Zhang, C.B. Westphalen, S. Boeck, M. Haas
Over the past two decades, our group has conducted five multicenter trials focusing on first-line systemic therapy for patients with advanced pancreatic cancer. The current pooled analysis was designed to evaluate prognosis over time and the impact of clinical characteristics on survival. Individual patient data were derived from five prospective, controlled, multicenter trials conducted by the ‘Arbeitsgemeinschaft
-
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers ESMO Open (IF 7.3) Pub Date : 2024-03-18 D. Nishizaki, R. Kurzrock, H. Miyashita, J.J. Adashek, S. Lee, M. Nikanjam, R.N. Eskander, H. Patel, G.P. Botta, M.K. Nesline, S. Pabla, J.M. Conroy, P. DePietro, J.K. Sicklick, S. Kato
Optimizing immune checkpoint inhibitor (ICI) therapy may require identification of co-targetable checkpoint pathways via immune profiling. Herein, we analyzed the transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation (VISTA), a promising targetable checkpoint. RNA sequencing was carried out on 514 tissues reflecting diverse advanced/metastatic
-
Elements of successful patient involvement in clinical cancer trials: a review of the literature ESMO Open (IF 7.3) Pub Date : 2024-03-15 I. Shakhnenko, O. Husson, D. Chuter, W. van der Graaf
Patient involvement in clinical cancer research has gained much ground in the past few years and studies demonstrated positive outcomes of such involvement. Yet, they also indicated a lack of evidence around best methods and practices to achieve successful patient involvement. The aim of this literature review was to provide a synthesis of elements contributing to successful and meaningful ways of
-
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma ESMO Open (IF 7.3) Pub Date : 2024-03-15 M. Caccese, I. Desideri, V. Villani, M. Simonelli, M. Buglione, S. Chiesa, E. Franceschi, P. Gaviani, I. Stasi, C. Caserta, S. Brugnara, I. Lolli, E. Bennicelli, P. Bini, A.S. Cuccu, S. Scoccianti, M. Padovan, S. Gori, A. Bonetti, P. Giordano, A. Pellerino, F. Gregucci, N. Riva, S. Cinieri, V. Internò, M. Santoni, G. Pernice, C. Dealis, L. Stievano, F. Paiar, G. Magni, G.L. De Salvo, V. Zagonel, G
In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting. The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse
-
Targeting the immune microenvironment in ovarian cancer therapy—mission impossible? ESMO Open (IF 7.3) Pub Date : 2024-03-15 F. Blanc-Durand, P. Pautier, J. Michels, A. Leary
-
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial ESMO Open (IF 7.3) Pub Date : 2024-03-11 J. Tabernero, J. Taieb, M. Fakih, G.W. Prager, E. Van Cutsem, F. Ciardiello, R.J. Mayer, N. Amellal, D. Skanji, E. Calleja, T. Yoshino
In metastatic colorectal cancer (mCRC), mutations are often associated with poorer survival; however, the prognostic impact of specific point mutations is unclear. In the phase III SUNLIGHT trial, trifluridine/tipiracil (FTD/TPI) plus bevacizumab significantly improved overall survival (OS) versus FTD/TPI alone. We assessed the impact of mutational status on OS in SUNLIGHT. In the global, open-label
-
Aggressive anticancer treatment in the last 2 weeks of life ESMO Open (IF 7.3) Pub Date : 2024-03-11 N. Golob, T. Oblak, L. Čavka, M. Kušar, B. Šeruga
There is a concern that terminally ill cancer patients may be aggressively treated due to the rapidly growing possibilities of anticancer treatment. The aim of this study was to evaluate the use of anticancer treatment at the end of life (EoL). This retrospective study included adult patients with advanced solid cancers who were treated at the Institute of Oncology Ljubljana and died of cancer between
-
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis ESMO Open (IF 7.3) Pub Date : 2024-03-10 G. Nader-Marta, M. Monteforte, E. Agostinetto, M. Cinquini, D. Martins-Branco, M. Langouo, A. Llombart-Cusac, J. Cortés, M. Ignatiadis, V. Torri, G. Apolone, V. Cappelletti, G. Pruneri, E. de Azambuja, S. Di Cosimo
The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess the prognostic value of ctDNA in patients with operable (non metastatic) BC. A systematic search of databases (PubMed/Medline, Embase, and CENTRAL) and conference proceedings was conducted to identify studies
-
Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population ESMO Open (IF 7.3) Pub Date : 2024-03-08 Q. Lu, N. Wang, K. Jiang, H. Zhou, P. Zhang, J. Zhang, S. Wang, P. Sun, F. Xu
Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). Formalin-fixed paraffin-embedded archived specimens including
-
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials ESMO Open (IF 7.3) Pub Date : 2024-03-06 L. Arenare, R. Di Liello, P. De Placido, C. Gridelli, A. Morabito, S. Pignata, F. Nuzzo, A. Avallone, E. Maiello, P. Gargiulo, C. Schettino, A. Gravina, C. Gallo, P. Chiodini, M. Di Maio, F. Perrone, M.C. Piccirillo
Oncologists tend to under-report subjective symptoms during cancer treatment. This study describes the under-reporting rate of selected symptoms and explores its association with overall survival (OS). A secondary aim is to test the association of patient-reported symptoms with OS. This is a analysis on data pooled from 12 randomized trials, promoted by the National Cancer Institute of Naples (Italy)
-
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer ESMO Open (IF 7.3) Pub Date : 2024-03-06 L.W. de Boo, K. Jóźwiak, N.D. Ter Hoeve, P.J. van Diest, M. Opdam, Y. Wang, M.K. Schmidt, V. de Jong, S. Kleiterp, S. Cornelissen, D. Baars, R.H.T. Koornstra, E.D. Kerver, T. van Dalen, A.D. Bins, A. Beeker, S.M. van den Heiligenberg, P.C. de Jong, S.D. Bakker, R.C. Rietbroek, I.R. Konings, R. Blankenburgh, R.M. Bijlsma, A.L.T. Imholz, N. Stathonikos, W. Vreuls, J. Sanders, E.H. Rosenberg, E.A. Koop
In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve
-
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer ESMO Open (IF 7.3) Pub Date : 2024-03-06 M. Marín-Aguilera, P. Jares, E. Sanfeliu, G. Villacampa, E. Hernández-lllán, A.I. Martínez-Puchol, S. Shankar, B. González-Farré, A.G. Waks, F. Brasó-Maristany, F. Pardo, D.K. Manning, J.A. Abery, J. Curaba, L. Moon, O. Gordon, P. Galván, P. Wachirakantapong, O. Castillo, C.M. Nee, P. Blasco, T.H. Senevirathne, V. Sirenko, O. Martínez-Sáez, A. Aguirre, I.E. Krop, Z. Li, P. Spellman, O. Metzger Filho
HER2DX, a multianalyte genomic test, has been clinically validated to predict breast cancer recurrence risk (relapse risk score), the probability of achieving pathological complete response post-neoadjuvant therapy (pCR likelihood score), and individual messenger RNA (mRNA) expression levels in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This study
-
Management of infusion-related reactions in cancer therapy: strategies and challenges ESMO Open (IF 7.3) Pub Date : 2024-03-06 A. Barroso, F. Estevinho, V. Hespanhol, E. Teixeira, J. Ramalho-Carvalho, A. Araújo
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B) ESMO Open (IF 7.3) Pub Date : 2024-03-04 G. Villacampa, T. Pascual, F. Brasó-Maristany, L. Paré, O. Martínez-Sáez, J. Cortés, E. Ciruelos, M. Martin, P. Conte, L.A. Carey, A. Fernandez, N. Harbeck, M. Marín-Aguilera, A. Vivancos, G. Curigliano, P. Villagrasa, J.S. Parker, C.M. Perou, A. Prat, S.M. Tolaney
The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer. In this study, we present the outcomes of the HER2DX risk-score within the most recent release of the Sweden Cancerome Analysis Network—Breast (SCAN-B) HER2+ cohort. This updated examination benefits from
-
Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies ESMO Open (IF 7.3) Pub Date : 2024-03-04 H. Wen, G. Deng, X. Shi, Z. Liu, A. Lin, Q. Cheng, J. Zhang, P. Luo
Identifying the association between body mass index (BMI) or weight change and cancer prognosis is essential for the development of effective cancer treatments. We aimed to assess the strength and validity of the evidence of the association between BMI or weight change and cancer prognosis by a systematic evaluation and meta-analysis of relevant cohort studies. We systematically searched the PubMed
-
Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer ESMO Open (IF 7.3) Pub Date : 2024-02-23 M. Bottosso, F. Mosele, S. Michiels, P.-H. Cournède, S. Dogan, C. Labaki, F. André
Tumor heterogeneity represents a major challenge in breast cancer, being associated with disease progression and treatment resistance. Precision medicine has been extensively applied to dissect tumor heterogeneity and, through a deeper molecular understanding of the disease, to personalize therapeutic strategies. In the last years, technological advances have widely improved the understanding of breast
-
Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM) ESMO Open (IF 7.3) Pub Date : 2024-02-23 R. Berardi, F. Rossi, R. Papa, M. Appetecchia, G. Baggio, M. Bianchini, T. Mazzei, A. Maria Moretti, E. Ortona, F. Pietrantonio, V. Tarantino, T. Vavalà, S. Cinieri
Following the development of gender medicine in the past 20 years, more recently in the field of oncology an increasing amount of evidence suggests gender differences in the epidemiology of cancers, as well as in the response and toxicity associated with therapies. In a gender approach, critical issues related to sexual and gender minority (SGM) populations must also be considered. A working group
-
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203) ESMO Open (IF 7.3) Pub Date : 2024-02-23 A.M. Di Giacomo, M. Schenker, J. Medioni, S. Mandziuk, M. Majem, G. Gravis, M. Cornfeld, S. Ranganathan, S. Lou, T. Csoszi
POD1UM-203, an open-label, multicenter, phase II study, evaluated retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1) in patients with selected solid tumors where immune checkpoint inhibitor therapies have previously shown efficacy. Eligible patients (≥18 years) had measurable disease and included unresectable or metastatic melanoma, treatment-naive metastatic
-
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing ESMO Open (IF 7.3) Pub Date : 2024-02-21 T. Takeshita, T. Iwamoto, N. Niikura, K. Watanabe, Y. Kikawa, K. Kobayashi, N. Iwakuma, T. Okamura, H. Tada, S. Ozaki, T. Okuno, U. Toh, Y. Yamamoto, M. Tsuneizumi, H. Ishiguro, N. Masuda, S. Saji
The FUTURE trial (UMIN000029294) demonstrated the safety and efficacy of adding palbociclib after fulvestrant resistance in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced and metastatic breast cancer (ABC/MBC). In this planned sub-study, cancer panel sequencing of cell-free DNA (cfDNA) was utilized to explore prognostic and predictive
-
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101) ESMO Open (IF 7.3) Pub Date : 2024-02-21 N. Lakhani, R. Cosman, U. Banerji, D. Rasco, M. Tomaszewska-Kiecana, E. Garralda, D. Kornacki, J. Li, C. Tian, N. Bourayou, J. Powderly
Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4κ monoclonal antibody against human programmed cell death protein 1 (PD-1). This first-in-human, phase I study assessed the safety and efficacy of retifanlimab in patients with advanced solid tumors and identified optimal dosing. POD1UM-101 was conducted in two parts: (i) dose escalation—evaluated retifanlimab [1 mg/kg every 2 weeks (q2w)
-
Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial ESMO Open (IF 7.3) Pub Date : 2024-02-19 C. Fan, Z. Jiang, C. Teng, X. Song, L. Li, W. Shen, Q. Jiang, D. Huang, Y. Lv, L. Du, G. Wang, Y. Hu, S. Man, Z. Zhang, N. Gao, F. Wang, T. Shi, T. Xin
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615). Patients with confirmed NSCLC-LM
-
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned ESMO Open (IF 7.3) Pub Date : 2024-02-15 J.S.W. Borgers, A.W. van Schijndel, J.V. van Thienen, S. Klobuch, T.T.P. Seijkens, R.P. Tobin, L. van Heerebeek, A. Driessen-Waaijer, M.W. Rohaan, J.B.A.G. Haanen
Treatment with tumor-infiltrating lymphocytes (TILs) is rapidly evolving for patients with solid tumors. Following metastasectomy, TILs (autologous, intratumoral CD4+ and CD8+ T cells with the potential to recognize tumor-associated antigens) are isolated and non-specifically expanded in the presence of interleukin-2 (IL-2). Subsequently, the TILs are adoptively transferred to the patients after a
-
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes ESMO Open (IF 7.3) Pub Date : 2024-02-12 M.A. Franzoi, M. Aupomerol, J. Havas, D. Soldato, M. Lambertini, C. Massarotti, H. Hang, B. Pistilli, L. Fasse, O. Tredan, E. Gillanders, F. Joly, P. Cottu, M.-A. Mouret-Reynier, C. Tarpin, A. Arnaud, S. Everhard, A.-L. Martin, A. Di Meglio, I. Vaz-Luis
Sexual concerns are a major unaddressed need among survivors of breast cancer (BC) with significant negative effects on quality of life. We longitudinally analyzed sexual health over time, using patient-reported outcomes. Patients with stage I-III BC prospectively included from the CANcer TOxicity cohort (CANTO) provided data at diagnosis, then 1, 2, and 4 years afterward. Sexual concerns outcomes
-
Controversies in upper GI oncology: maintenance treatment in pancreatic cancer ESMO Open (IF 7.3) Pub Date : 2024-02-12 J. Dekervel, D. Laheru, E.M. O’Reilly
-
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial ESMO Open (IF 7.3) Pub Date : 2024-02-12 S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell,
In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the final analysis of OS, systemic and intracranial activity, and the impact of co-occurring aberrations. EUCROSS
-
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma ESMO Open (IF 7.3) Pub Date : 2024-02-12 Y.M. Geurts, S.I.M. Neppelenbroek, B.M.P. Aleman, C.P.M. Janus, A.D.G. Krol, D.J. van Spronsen, W.J. Plattel, J.M. Roesink, K.M.S. Verschueren, J.M. Zijlstra, H.R. Koene, M.R. Nijziel, E.C. Schimmel, E. de Jongh, F. Ong, L.C.J. te Boome, R.S. van Rijn, L.H. Böhmer, B.D.P. Ta, H.P.J. Visser, E.F.M. Posthuma, Y.M. Bilgin, K. Muller, D. van Kampen, C. So-Osman, J.S.P. Vermaat, R.J. de Weijer, M.J. Kersten
The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising
-
Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care ESMO Open (IF 7.3) Pub Date : 2024-02-12 J.M. Ribeiro, J. Dixon-Douglas, F. André
-
Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021 ESMO Open (IF 7.3) Pub Date : 2024-02-09 V. Grumberg, F.-E. Cotté, E. Giroux-Leprieur, A.-F. Gaudin, C. Lebbé, I. Borget
In France, the potential benefit of new treatments is initially evaluated by the Haute Autorité de Santé to determine reimbursement and pricing, but rarely afterwards. Although immunotherapies (ITs) have considerably improved the survival of patients, few data are available on their long-term benefit at a population-treated level. The present retrospective study aimed to assess the clinical benefit
-
Controversies in upper GI oncology: first-line systemic treatment in MASLD-associated HCC ESMO Open (IF 7.3) Pub Date : 2024-02-08 J. Dekervel, A. Casadei-Gardini, M. Pinter
-
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study ESMO Open (IF 7.3) Pub Date : 2024-02-06 L. Yi, Z. Ning, L. Xu, Y. Shen, X. Zhu, W. Yu, J. Xie, Z. Meng
H101, an innovative oncolytic adenovirus, has shown potential in modifying the tumor microenvironment from immunologically ‘cold’ to ‘hot’. When combined with nivolumab, a programmed cell death protein 1 inhibitor, this synergy may offer substantial therapeutic benefits beyond the capabilities of each agent alone. In this pilot study, we assessed the efficacy and safety of combining H101 with nivolumab
-
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis ESMO Open (IF 7.3) Pub Date : 2024-02-05 I. Michelon, M. Vilbert, A.D. Marinho, C.E.R. Castro, M.I. Dacoregio, C. Stecca, L.R. Soares, M.V. Batista, S. Braga, A. Saeed, L. Cavalcante
Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor receptor 2 (HER2)-positive BCBM population. We searched PubMed, Embase, and Cochrane Library databases as well as American Society of Clinical Oncology
-
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors ESMO Open (IF 7.3) Pub Date : 2024-02-05 B. Perez, R. Aljumaily, T.U. Marron, M.R. Shafique, H. Burris, W.T. Iams, S.J. Chmura, J.J. Luke, W. Edenfield, D. Sohal, X. Liao, C. Boesler, A. Machl, J. Seebeck, A. Becker, B. Guenther, A. Rodriguez-Gutierrez, S.J. Antonia
We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced solid tumors. Peposertib 100-400 mg twice daily (b.i.d.) or 100-250 mg once daily (q.d.) was administered in combination with avelumab 800 mg every 2 weeks in
-
Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer ESMO Open (IF 7.3) Pub Date : 2024-02-05 G.A. Martens, J. Demol, F. Dedeurwaerdere, J. Breyne, K. De Smet, P. De Jaeger, D. De Smet
The use of circulating tumor DNA (ctDNA) concentration for metastatic cancer surveillance is promising, but uncertainty remains about cut-offs with clinical validity. This observational study recruited 136 subjects with advanced metastatic breast cancer (irrespective of /hormone receptor status) for sequencing of their primary tumor in search for hotspot variants amenable for monitoring by droplet
-
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer ESMO Open (IF 7.3) Pub Date : 2024-02-03 K. Shitara, T. Fleitas, H. Kawakami, G. Curigliano, Y. Narita, F. Wang, S.O. Wardhani, M. Basade, S.Y. Rha, W.I. Wan Zamaniah, D.L. Sacdalan, M. Ng, K.H. Yeh, P. Sunpaweravong, E. Sirachainan, M.-H. Chen, W.P. Yong, J.L. Peneyra, M.N. Ibtisam, K.-W. Lee, V. Krishna, R.R. Pribadi, J. Li, A. Lui, T. Yoshino, E. Baba, I. Nakayama, G. Pentheroudakis, H. Shoji, A. Cervantes, C. Ishioka, E. Smyth
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus
-
Sexual quality of life of adolescents and young adult breast cancer survivors ESMO Open (IF 7.3) Pub Date : 2024-01-27 N.J.M.C. Vrancken Peeters, C. Vlooswijk, R.M. Bijlsma, S.E.J. Kaal, J.M. Kerst, J.M. Tromp, M.E.M.M. Bos, T. van der Hulle, R.I. Lalisang, J. Nuver, M.C.M. Kouwenhoven, I.M.C. van der Ploeg, W.T.A. van der Graaf, O. Husson
With increasing survival rates of adolescents and young adults (AYAs) with breast cancer, health-related quality of life (HRQoL) becomes more important. An important aspect of HRQoL is sexual QoL. This study examined long-term sexual QoL of AYA breast cancer survivors, compared sexual QoL scores with that of other AYA cancer survivors, and identified factors associated with long-term sexual QoL of
-
Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era ESMO Open (IF 7.3) Pub Date : 2024-01-24 G. Hagopian, X. Jiang, C. Grant, D. Brazel, P. Kumar, M. Yamamoto, J. Jakowatz, W. Chow, T. Tran, W. Shen, J. Moyers
Checkpoint inhibitors have shown improvement in recurrence-free survival in the post-operative setting for node-positive melanoma and were first approved in late 2015. However, single-agent checkpoint therapies have yet to show benefit to overall survival (OS) for lower-risk stage III cancers. We evaluated the OS benefit of post-operative immunotherapy in the National Cancer Database (NCDB). Patient
-
Expanding Horizons in Oncology: A Vision for ESMO Open ESMO Open (IF 7.3) Pub Date : 2024-01-23 G. Curigliano
-
-
-
Prevalence and factors associated with professional burnout in Polish oncologists—results of a nationwide survey ESMO Open (IF 7.3) Pub Date : 2024-01-23 P. Sobczuk, A. Gawlik-Urban, D. Sigorski, J. Kiszka, M. Osmola, K. Machulska-Ciuraj, M. Wilk, A. Brodziak
High rates of burnout are observed among health care professionals worldwide, which could have negative consequences on personal and organizational levels. We aimed to evaluate the burnout prevalence and factors associated with burnout among oncologists in Poland. An online survey was conducted using the validated Maslach Burnout Inventory—Human Services Survey (MBI-HSS) and additional work/lifestyle
-
22P PD-L1 testing in mTNBC: Interplatform and interobserver reproducibility of CE-IVD assays for CPS and IC scores ESMO Open (IF 7.3) Pub Date : 2024-01-21 N. Fusco, M. Ivanova, C. Frascarelli, B. Cerbelli, G. Pignataro, C. Criscitiello, K. Venetis, E. Sajjadi, E. Guerini-Rocco, P. Graziano, M. Martini, G. D'Amati
-
24P Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer ESMO Open (IF 7.3) Pub Date : 2024-01-21 A. Karlsson, F. Killander, D.F.N. Oliveira, F. Rosengren, J. Vallon-Christersson, J. Staaf
-
23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC) ESMO Open (IF 7.3) Pub Date : 2024-01-21 M. Nunez Abad, J.Á. García García, S. Torres-Martínez, M. Lobo de Mena, F. Ben Hammou El Majdoubi, M. Mosqueda-Frometa, C. Camps Herrero, S. Calabuig Fariñas, V. Iranzo
-
The increasing burden of testicular seminomas and non-seminomas in adolescents and young adults (AYAs): incidence, treatment, disease-specific survival and mortality trends in the Netherlands between 1989 and 2019 ESMO Open (IF 7.3) Pub Date : 2024-01-19 D.J. van der Meer, H.E. Karim-Kos, H.W. Elzevier, M. Dinkelman-Smit, J.M. Kerst, V. Atema, V. Lehmann, O. Husson, W.T.A. van der Graaf
Testicular cancer incidence among adolescents and young adults (AYAs, aged 18-39 years at diagnosis) is increasing worldwide and most patients will survive the initial disease. Still, detailed epidemiological information about testicular cancer among AYAs is scarce. This study aimed to provide a detailed overview of testicular cancer trends in incidence, treatment, long-term relative survival and mortality
-
Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma ESMO Open (IF 7.3) Pub Date : 2024-01-19 A. Petrillo, S. Derks, E.C. Smyth
Abstract not available
-
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis ESMO Open (IF 7.3) Pub Date : 2024-01-16 T. Landré, A. Karaboué, Z.S. Buchwald, P.F. Innominato, D.C. Qian, J.B. Assié, C. Chouaïd, F. Lévi, B. Duchemann
Immune checkpoint inhibitors (ICIs) have become the standard of care for numerous malignancies. Emerging evidence suggests that the time of day (ToD) of ICI administration could impact the outcomes of patients with cancer. The consistency of ToD effects on ICI efficacy awaits initial evaluation. This meta-analysis integrates progression-free survival (PFS) and overall survival (OS) data from studies
-
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy? ESMO Open (IF 7.3) Pub Date : 2024-01-16 C. Benvenuti, L. Laot, T. Grinda, M. Lambertini, B. Pistilli, M. Grynberg
Controlled ovarian stimulation (COS) for oocyte/embryo cryopreservation is the method of choice for fertility preservation (FP) in young patients diagnosed with early-stage breast cancer (eBC). Nevertheless, some challenges still question its role, particularly in the neoadjuvant setting, where concerns arise about potential delay in the onset of anticancer treatment, and in hormone receptor-positive
-
Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine ESMO Open (IF 7.3) Pub Date : 2024-01-09 A. Di Meglio, I. Vaz-Luis
Abstract not available
-
Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study ESMO Open (IF 7.3) Pub Date : 2024-01-09 D.-W. Kang, S.-K. Park, Y.L. Yu, Y. Lee, D.H. Lee, S. Kang
Background Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-small-cell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods This was a retrospective cohort study
-
Novel trial designs for patients with gastrointestinal stromal tumor ESMO Open (IF 7.3) Pub Date : 2024-01-08 C. Serrano, S. Rothschild, G. Villacampa, M.C. Heinrich, S. George, J.-Y. Blay, J.K. Sicklick, G.K. Schwartz, S. Rastogi, R.L. Jones, P. Rutkowski, N. Somaiah, V. Navarro, D. Evans, J.C. Trent
Abstract not available
-
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study ESMO Open (IF 7.3) Pub Date : 2024-01-08 J. Keyl, A. Bucher, F. Jungmann, R. Hosch, A. Ziller, R. Armbruster, P. Malkomes, T.M. Reissig, S. Koitka, I. Tzianopoulos, P. Keyl, K. Kostbade, D. Albers, P. Markus, J. Treckmann, K. Nassenstein, J. Haubold, M. Makowski, M. Forsting, H.A. Baba, R. Braren
Background Despite the prognostic relevance of cachexia in pancreatic cancer, individual body composition has not been routinely integrated into treatment planning. In this multicenter study, we investigated the prognostic value of sarcopenia and myosteatosis automatically extracted from routine computed tomography (CT) scans of patients with advanced pancreatic ductal adenocarcinoma (PDAC). Patients
-
Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial ESMO Open (IF 7.3) Pub Date : 2024-01-09 C. Chen, Z. Li, X. Xiong, A. Yao, S. Wang, X. Liu, X. Liu, J. Wang
Background Advanced primary liver cancer patients with malignant ascites have a poor prognosis and lack effective treatment plans. This phase Ib study aims to explore the safety and clinical efficacy of intraperitoneal anti-programmed cell death protein 1 (PD-1) antibody in these patients. Patients and methods Patients received sintilimab 100 mg intraperitoneally plus best supportive care on days 1
-
Corrigendum to “Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer”: [ESMO Open 8 (2023) 100762] ESMO Open (IF 7.3) Pub Date : 2024-01-08 Y. Kubota, A. Kawazoe, S. Mishima, Y. Nakamura, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, T. Doi, T. Yoshino, T. Kuwata, K. Shitara
Abstract not available
-
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting ESMO Open (IF 7.3) Pub Date : 2024-01-11 J. Herrstedt, R. Clark-Snow, C.H. Ruhlmann, A. Molassiotis, I. Olver, B.L. Rapoport, M. Aapro, K. Dennis, P.J. Hesketh, R.M. Navari, L. Schwartzberg, M.L. Affronti, M.A. Garcia-Del-Barrio, A. Chan, L. Celio, R. Chow, M. Fleury, R.J. Gralla, R. Giusti, F. Jahn, H. Iihara, E. Maranzano, V. Radhakrishnan, M. Saito, P. Sayegh, S. Bosnjak, L. Zhang, J. Lee, V. Ostwal, T. Smit, A. Zilic, K. Jordan, F. Scotté
Abstract not available
-
Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018 ESMO Open (IF 7.3) Pub Date : 2024-01-02 D.J. van der Meer, W.T.A. van der Graaf, D. van de Wal, H.E. Karim-Kos, O. Husson
Background Few studies have comprehensively investigated the long-term second cancer risk among adolescent and young adult (AYA, aged 15-39 years) cancer survivors. This study investigated the long-term second cancer risk by including the full range of first and second cancer combinations with at least 10 observations in the Netherlands between 1989 and 2018. Materials and methods First and second
-
PP460 Which chemotherapy information do cancer patients and caregivers have difficulty to understand? ESMO Open (IF 7.3) Pub Date : 2024-01-02 Seyoung Lee, Nayeon Kim, Hoyoung Kim, Misun Yi, Ayoung Lee, Juhee Cho
-
PP402 Correlation of plasma cytokine levels and tumor response after EGFR tyrosine kinase inhibitor treatment in advanced EGFR-mutated non-small cell lung cancer ESMO Open (IF 7.3) Pub Date : 2024-01-02 Nussara Pakvisal, Warissara Khuntharuks, Pornrat Kongkavitoon, Piyada Sitthideatphaiboon, Skunn Santisukwongchote, Pongsakorn Ouwongprayoon, Krittiya Korphaisarn, Chatchawit Aporntewan, Virote Sriuranpong, Chanida Vinayanuwattikun
-
PP147 Intraoperative radiographic evaluation of the resection margins in breast-conserving surgery with the usage of digital two-point sectorography in patients with breast cancer ESMO Open (IF 7.3) Pub Date : 2024-01-02 Yana Bondarchuk, Petr Krivorotko, Sergey Bagnenko, Elena Zhiltsova, Antonina Chernaya, Anna Artemyeva, Tengiz Tabagua, Larisa Gigolaeva, Alexander Komyakhov, Kirill Nikolaev, Nikolay Amirov, Roman Pesotsky, Alexander Emelyanov, Victoria Mortada, Konstantin Zernov, Sergey Yerechshenko, Diana Enaldieva, Vladimir Semiglazov
-
PP051 RNA-seq analysis of CRISPR-Cas9 targeted AGR2 of breast cancer cells reveals potential modulators of its expression and secretion ESMO Open (IF 7.3) Pub Date : 2024-01-02 M. Aiman Mohtar, Syazalina Zahari, Nisa Syakila A. Rahman, Saiful Effendi, Muhammad-Redha Abdullah-Zawawi, Teck Yew Low, Ted Hupp
-
PP022 Establishment of an open standard for identification of HRD and patient susceptibility to PARPi ESMO Open (IF 7.3) Pub Date : 2024-01-02 Lea Milling Korsholm, Maj Kjeldsen, Lorenzo Perino, Luca Mariani, Gitte-Bettina Nyvang, Elisabeth Kristensen, Frederik Otzen Bagger, Mansoor Raza Mirza, Maria Rossing